Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 36

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

De novo design of covalent bonding peptides for target protein

Zhou, Xiaohong, Zhu, Qian, Zheng, Anqi, Xue, Boyuan, Wang, Qihui, Chin, Lip Ket, Jiang, Jingkun, He, Miao·2024·hLife

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.hlife.2024.07.007

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 37

  1. Day, 2021, Multidisciplinary approaches identify compounds that bind to human ACE2 or SARS-CoV-2 spike protein as candidates to block SARS-CoV-2-ACE2 receptor interactions, mBio, 12, 10.1128/mBio.03681-20 · DOI
  2. Sun, 2021, Aptamer blocking strategy inhibits SARS-CoV-2 virus infection, Angew Chem Int Ed Engl, 60, 10266, 10.1002/anie.202100225 · DOI · Paper page
  3. Han, 2020, Computational design of ACE2-based peptide inhibitors of SARS-CoV-2, ACS Nano, 14, 5143, 10.1021/acsnano.0c02857 · DOI · Paper page
  4. Qin, 2021, Covalent bonding aptamer with enhanced SARS-CoV-2 RBD-ACE2 blocking and pseudovirus neutralization activities, ChemRxiv
  5. Uraki, 2022, Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2, Nature, 607, 119, 10.1038/s41586-022-04856-1 · DOI · Paper page
  6. Tang, 2022, AI-aided design of novel targeted covalent inhibitors against SARS-CoV-2, Biomolecules, 12, 746, 10.3390/biom12060746 · DOI
  7. Han, 2022, Covalently engineered protein minibinders with enhanced neutralization efficacy against escaping SARS-CoV-2 variants, J Am Chem Soc, 144, 5702, 10.1021/jacs.1c11554 · DOI
  8. Cui, 2012, Biomimetic peptide nanosensors, Acc Chem Res, 45, 696, 10.1021/ar2002057 · DOI
  9. Ling, 2020, In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2, Peptides, 130, 10.1016/j.peptides.2020.170328 · DOI
  10. Zhang, 2020, The first-in-class peptide binder to the SARS-CoV-2 spike protein, bioRxiv
  11. Pomplun, 2021, De novo discovery of high-affinity peptide binders for the SARS-CoV-2 spike protein, ACS Cent Sci, 7, 156, 10.1021/acscentsci.0c01309 · DOI
  12. Zhu, 2022, A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair, J Hazard Mater, 425, 10.1016/j.jhazmat.2021.127923 · DOI
  13. Yin, 2021, Rational design of potent peptide inhibitors of the PD-1:PD-L1 interaction for cancer immunotherapy, J Am Chem Soc, 143, 18536, 10.1021/jacs.1c08132 · DOI · Paper page
  14. Berdan, 2021, Covalent peptides and proteins for therapeutics, Biorg Med Chem, 29, 10.1016/j.bmc.2020.115896 · DOI
  15. Hoppmann, 2016, Proximity-enabled bioreactivity to generate covalent peptide inhibitors of p53–Mdm4, Chem Commun, 52, 5140, 10.1039/C6CC01226D · DOI
  16. Narayanan, 2015, Sulfonyl fluorides as privileged warheads in chemical biology, Chem Sci, 6, 2650, 10.1039/C5SC00408J · DOI · Paper page
  17. Marze, 2018, Efficient flexible backbone protein–protein docking for challenging targets, Bioinformatics, 34, 3461, 10.1093/bioinformatics/bty355 · DOI · Paper page
  18. Sedan, 2016, Peptiderive server: Derive peptide inhibitors from protein–protein interactions, Nucleic Acids Res, 44, W536, 10.1093/nar/gkw385 · DOI
  19. Gambini, 2020, Stability and cell permeability of sulfonyl fluorides in the design of Lys-covalent antagonists of protein-protein interactions, ChemMedChem, 15, 2176, 10.1002/cmdc.202000355 · DOI
  20. London, 2014, Covalent docking of large libraries for the discovery of chemical probes, Nat Chem Biol, 10, 1066, 10.1038/nchembio.1666 · DOI · Paper page
  21. Martin, 2019, Characterising covalent warhead reactivity, Bioorg Med Chem, 27, 2066, 10.1016/j.bmc.2019.04.002 · DOI
  22. Jones, 2020, Structure-based design and analysis of SuFEx chemical probes, RSC Med Chem, 11, 10, 10.1039/C9MD00542K · DOI
  23. Lamiable, 2016, PEP-FOLD3: Faster de novo structure prediction for linear peptides in solution and in complex, Nucleic Acids Res, 44, W449, 10.1093/nar/gkw329 · DOI · Paper page
  24. Hanoulle, 2006, A new functional, chemical proteomics technology to identify purine nucleotide binding sites in complex proteomes, J Proteome Res, 5, 3438, 10.1021/pr060313e · doi:10.1021/pr060313e
  25. Liu, 2021, Ultrasensitive detection of endocrine disruptors via superfine plasmonic spectral combs, Light Sci Appl, 10, 181, 10.1038/s41377-021-00618-2 · doi:10.1038/s41377-021-00618-2
  26. Almehdi, 2021, SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies, Infection, 49, 855, 10.1007/s15010-021-01677-8 · DOI
  27. Koyama, 2020, Variant analysis of SARS-CoV-2 genomes, Bull World Health Organ, 98, 495, 10.2471/BLT.20.253591 · DOI · Paper page
  28. Viana, 2022, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa, Nature, 603, 679, 10.1038/s41586-022-04411-y · DOI · Paper page
  29. Iketani, 2022, Antibody evasion properties of SARS-CoV-2 Omicron sublineages, Nature, 604, 553, 10.1038/s41586-022-04594-4 · DOI · Paper page
  30. Odolczyk, 2022, Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2, Front Mol Biosci, 9, 10.3389/fmolb.2022.983014 · DOI
  31. Wang, 2022, In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery, J Med Virol, 94, 1766, 10.1002/jmv.27540 · doi:10.1002/jmv.27540
  32. Wang, 2021, An overview of kinase downregulators and recent advances in discovery approaches, Signal Transduct Targeted Ther, 6, 423, 10.1038/s41392-021-00826-7 · DOI
  33. Kagami, 2023, The ACPYPE web server for small-molecule MD topology generation, Bioinformatics, 39, 10.1093/bioinformatics/btad350 · DOI · Paper page
  34. Kumari, 2014, g_mmpbsa—a GROMACS tool for high-throughput MM-PBSA calculations, J Chem Inf Model, 54, 1951, 10.1021/ci500020m · DOI · Paper page
  35. Olsson, 2011, PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions, J Chem Theor Comput, 7, 525, 10.1021/ct100578z · DOI · Paper page
  36. Orsburn, 2021, Proteome discoverer—a community enhanced data processing suite for protein informatics, Proteomes, 9, 15, 10.3390/proteomes9010015 · DOI · Paper page
  37. Takashita, 2022, Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2, N Engl J Med, 386, 1475, 10.1056/NEJMc2201933 · DOI

Metadata

Authors
Zhou, X., Zhu, Q., Zheng, A., Xue, B., Wang, Q., Chin, L. K., Jiang, J., & He, M.
Venue
hLife
Publisher
Elsevier BV
Published
2024-12
Volume
2
Issue
12
Pages
641-652
ISSN
2949-9283
Cited by
36
References
3
Language
en
Licence
Funders
National Natural Science Foundation of China (52091541)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: De novo design of covalent bonding peptides for target protein. https://app.cochat.ai/papers/10.1016/j.hlife.2024.07.007
The paper
Zhou, X., Zhu, Q., Zheng, A., Xue, B., Wang, Q., Chin, L. K., Jiang, J., & He, M. (2024). De novo design of covalent bonding peptides for target protein. hLife. https://doi.org/10.1016/j.hlife.2024.07.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.